TAG:
molecular testing
Astorg Makes Billion-Dollar Bet on Microbiology Testing
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to …
Risk of Complacency May Be the Biggest Threat
Prevailing sentiment at the recent Executiv…
Expect RESULTS Act Vote by End of the Year
CEO SUMMARY: Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scruti…
Payers Unleash AI to Dissect Outlier Billing Patterns
Diagnostic laboratories can follow every clinical guideline, employ the most talented clinical lab professionals, and provide life-saving data to patients, yet still find themselves in the crosshairs of a federal or payer audit. The culprit is …
Lab Specimen Logistics Reach into the Home
Simple, at-home collection of blood samples could go a long way toward improving the patient experience while creating new opportunities for clinical laboratories. But it also presents unique logistical challenges as labs find themselves operating in a more consu…
Boosting Path Revenue with POC Services
CEO SUMMARY: The concept sounds simple—bring mobile point-of-care pathology services to physician offices and ambulatory surgical centers via specially equipped vehicles. Doctors Pathology Services explains some of the road bumps it hit along the way while also uncoverin…
Abbott Bets Hard on Cancer Diagnostics with New Deal
Abbott Laboratories’ deal to acquire Exact Sciences for $23 billion emphasizes the value that the in vitro diagnostics (IVD) manufacturer puts on cancer testing. Clinical laboratories involved with oncology should monitor the progres…
What Private Equity Sees in Diagnostics
CEO SUMMARY: Hologic’s acquisition by private equity firms Blackstone and TPG marks one of the year’s largest in vitro diagnostics transactions and a clear vote of confidence in the sector’s resilience. Industry analyst Bruce Carlson unpacks what the buyout …
Managing Denials and Appeals of Clinical Lab, Path Claims
CEO SUMMARY: Based on a study of denials and appeals involving about 20 million lab test claims, the team at XiFin Inc. presents here their findings. They also provide recommendations on steps labs can take to reduce denials and win a greater proportion of appeals. IN RECENT…
Despite COVID-19 Losses, IVD Executives Remain Upbeat
Continuing declines in COVID-19 test revenues was a common theme during the first quarte…
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.